This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Email citation

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Review

. 2008:46:205-80.

doi: 10.1016/S0079-6468(07)00005-7.

Histone deacetylase inhibitors: a novel class of anti-cancer agents on its way to the market

Matthias Körner¹, Ulrich Tibes

Affiliations

PMID: 18381127
DOI: 10.1016/S0079-6468(07)00005-7

Review

Histone deacetylase inhibitors: a novel class of anti-cancer agents on its way to the market

Matthias Körner et al. Prog Med Chem. 2008.

. 2008:46:205-80.

doi: 10.1016/S0079-6468(07)00005-7.

Authors

Matthias Körner¹, Ulrich Tibes

Affiliation

¹ Roche Diagnostics GmbH, Pharma Research Penzberg, 82372 Penzberg, Germany.

PMID: 18381127
DOI: 10.1016/S0079-6468(07)00005-7

No abstract available

PubMed Disclaimer

Similar articles

Identification of a series of substituted 2-piperazinyl-5-pyrimidylhydroxamic acids as potent histone deacetylase inhibitors.
Angibaud P, Van Emelen K, Decrane L, van Brandt S, Ten Holte P, Pilatte I, Roux B, Poncelet V, Speybrouck D, Queguiner L, Gaurrand S, Mariën A, Floren W, Janssen L, Verdonck M, van Dun J, van Gompel J, Gilissen R, Mackie C, Du Jardin M, Peeters J, Noppe M, Van Hijfte L, Freyne E, Page M, Janicot M, Arts J. Angibaud P, et al. Bioorg Med Chem Lett. 2010 Jan 1;20(1):294-8. doi: 10.1016/j.bmcl.2009.10.118. Epub 2009 Oct 30. Bioorg Med Chem Lett. 2010. PMID: 19906529
Identification of type-specific anticancer histone deacetylase inhibitors: road to success.
Noureen N, Rashid H, Kalsoom S. Noureen N, et al. Cancer Chemother Pharmacol. 2010 Sep;66(4):625-33. doi: 10.1007/s00280-010-1324-y. Epub 2010 Apr 17. Cancer Chemother Pharmacol. 2010. PMID: 20401613 Review.
A novel anti-cancer bifunctional platinum drug candidate with dual DNA binding and histone deacetylase inhibitory activity.
Griffith D, Morgan MP, Marmion CJ. Griffith D, et al. Chem Commun (Camb). 2009 Nov 28;(44):6735-7. doi: 10.1039/b916715c. Epub 2009 Oct 12. Chem Commun (Camb). 2009. PMID: 19885462
Design and synthesis of novel isoxazole-based HDAC inhibitors.
Conti P, Tamborini L, Pinto A, Sola L, Ettari R, Mercurio C, De Micheli C. Conti P, et al. Eur J Med Chem. 2010 Sep;45(9):4331-8. doi: 10.1016/j.ejmech.2010.06.035. Epub 2010 Jun 30. Eur J Med Chem. 2010. PMID: 20637529
[Structure-activity relationships of histone deacetylase inhibitors].
Tan YM, Huang WY, Yu NF. Tan YM, et al. Yao Xue Xue Bao. 2009 Oct;44(10):1072-83. Yao Xue Xue Bao. 2009. PMID: 20055127 Review. Chinese.

See all similar articles

Cited by

Binding ensemble profiling with photoaffinity labeling (BEProFL) approach: mapping the binding poses of HDAC8 inhibitors.
He B, Velaparthi S, Pieffet G, Pennington C, Mahesh A, Holzle DL, Brunsteiner M, van Breemen R, Blond SY, Petukhov PA. He B, et al. J Med Chem. 2009 Nov 26;52(22):7003-13. doi: 10.1021/jm9005077. J Med Chem. 2009. PMID: 19886628 Free PMC article.
Design, synthesis, docking, and biological evaluation of novel diazide-containing isoxazole- and pyrazole-based histone deacetylase probes.
Neelarapu R, Holzle DL, Velaparthi S, Bai H, Brunsteiner M, Blond SY, Petukhov PA. Neelarapu R, et al. J Med Chem. 2011 Jul 14;54(13):4350-64. doi: 10.1021/jm2001025. Epub 2011 Jun 2. J Med Chem. 2011. PMID: 21548582 Free PMC article.
The Impact of Histone Modifications in Endometriosis Highlights New Therapeutic Opportunities.
Psilopatis I, Vrettou K, Fleckenstein FN, Theocharis S. Psilopatis I, et al. Cells. 2023 Apr 23;12(9):1227. doi: 10.3390/cells12091227. Cells. 2023. PMID: 37174627 Free PMC article. Review.
A Review on Molecular Docking on HDAC Isoforms: Novel Tool for Designing Selective Inhibitors.
Drakontaeidi A, Pontiki E. Drakontaeidi A, et al. Pharmaceuticals (Basel). 2023 Nov 22;16(12):1639. doi: 10.3390/ph16121639. Pharmaceuticals (Basel). 2023. PMID: 38139766 Free PMC article. Review.
Novel hybrid molecule overcomes the limited response of solid tumours to HDAC inhibitors via suppressing JAK1-STAT3-BCL2 signalling.
Huang Z, Zhou W, Li Y, Cao M, Wang T, Ma Y, Guo Q, Wang X, Zhang C, Zhang C, Shen W, Liu Y, Chen Y, Zheng J, Yang S, Fan Y, Xiang R. Huang Z, et al. Theranostics. 2018 Oct 5;8(18):4995-5011. doi: 10.7150/thno.26627. eCollection 2018. Theranostics. 2018. PMID: 30429882 Free PMC article.

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science